HOME PAGE > La actualidad de Chiesi

La actualidad de Chiesi

-
03/07/2020
-
See more
 
-
17/06/2020
-
See more
 
Chiesi España pone en valor los conocimientos de...
30/04/2020
En el marco del Día Nacional de Fibrosis Quística   Barcelona, 30 de abril de 2020. Todos los esfuerzos de...
See more
Chiesi colabora junto a profesionales sanitarios...
20/04/2020
-
See more
 
-
30/01/2020
-
See more
 
-
26/04/2018
-
See more
-
26/04/2018
-
See more
 
-
13/04/2018
-
See more
 
Chiesi Group receives the European Marketing...
04/04/2018
  Lamzede® (velmanase alfa) is the first enzyme replacement therapy for the treatment of non-neurological...
See more
Chiesi Spain and Richi Entrepreneurs launch the...
22/03/2018
-
See more
 
-
18/03/2018
-
See more
 
-
22/02/2018
-
See more
New study published in The Lancet shows Trimbow®...
12/02/2018
  The TRIBUTE study showed superiority of Chiesi’s triple extrafine formulation Trimbow® over Ultibro®...
See more
 
Chiesi Group receives positive opinion from CHMP...
29/01/2018
Lamzede® (velmanase alfa) is the first pharmacological therapy for the treatment of Alpha Mannosidosis, an ultra-rare,...
See more
 
"Internal entrepreneurs are key to the evolution...
23/01/2018
Thanks to intrapreneurship, the organization's culture can be developed by innovative ideas or projects while increasing...
See more
Chiesi leads the ranking of italian companies...
02/01/2018
  The EU Industrial R & D Investment Ranking of the European Commission in 2017 places the Chiesi Group at the top of...
See more
 
Balanced nutrition helps prevent decompensation...
21/12/2017
-
See more
 
-
30/11/2017
-
See more
-
30/11/2017
-
See more
 
-
28/11/2017
-
See more
 
-
03/11/2017
-
See more
CHIESI ENTERS INTO AN EXCLUSIVE EX-US PARTNERSHIP...
25/10/2017
    Protalix grants Chiesi Ex-US rights to PRX-102, a chemically modified version of the recombinant protein...
See more
 
TRIBUTE study shows superiority of Chiesi’s...
07/09/2017
  Chiesi completed a long-term clinical study with its extrafine fixed triple combination (Trimbow®) in COPD...
See more
 
-
07/09/2017
-
See more
Chiesi Group receives the European Marketing...
24/07/2017
Chiesi Group receives the European Marketing Authorisation for Trimbow® (ICS/LABA/LAMA)     Parma, Italy July...
See more
 
Chiesi Farmaceutici completes the acquisition of...
23/06/2017
Chiesi Farmaceutici completes the acquisition of European Marketing Rights to PROCYSBI® (cysteamine bitartrate)...
See more
 
Respiration Day 2017
28/05/2017
 The present and future of chronic obstructive pulmonary disease is the focus of the Respiration Day 2017: from the new GOLD...
See more
"Between 10-15% of cases of asthma in adults can...
24/05/2017
This type of asthma has become the most common occupational lung disease in developed countries1  It is due to the...
See more
 
-
22/05/2017
       
See more
 
-
17/05/2017
-
See more
-
08/05/2017
-
See more
 
Chiesi Group reports an increased turnover in...
26/04/2017
Chiesi Group reports an increased turnover in 2016 and consolidates its global presence     Chiesi Group closes...
See more
 
The Chiesi Group increases its turnover in 2016...
26/04/2017
The Chiesi Group closes 2016 with a turnover of 571 million euros, 7.0% more than in 2015 (+9.6% with a constant exchange...
See more
GLYBERA▼ (ALIPOGENE TIPARVOVEC) IN EUROPE
20/04/2017
GLYBERA▼ (ALIPOGENE TIPARVOVEC) IN EUROPE   Parma, 20 April 2017 - Chiesi Farmaceutici Spa (“Chiesi”)...
See more
 
-
04/04/2017
-
See more
 
-
29/03/2017
-
See more